2009 Annual Results Fosun International

This presentation and the presentation materials distributed herewith include forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited (the “Company”) expects or anticipates will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The Company’s actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risks and factors beyond our control. In addition, the Company makes the forward- looking statements referred to herein as of today and undertakes no obligation to update these statements. Contents

¾ 2009 Group Overview ¾ 2009 Financial Review ¾ 2009 Business Review • Operational performance by segment • Investments and returns • Financing from multiple sources ¾ Vision and Outlooks Fosun at a Glance

Effective shareholding as of May 31, 2010

Fosun Holdings Public Shareholders

78.2% 21.8%

Fosun International (00656.HK) Hong Kong 100% Mainland China Fosun Group

Property Retail, Services & Pharmaceuticals Steel Mining Strategic Development Investments

Fosun Pharma NSU Hainan Mining Yuyuan Forte (02337.HK) (600196.SH) 60.0% 60.0% (Fe) (600655.SH) 49.0% 70.6% 17.3% 62.7% Jin'an Mining 34.0% 19.8% Nanjing Iron & 60.0% (Fe) Yong’an Insurance Sinopharm Steel Zendai (00755.HK) (600282.SH) 14.6% (01099.HK) Huaxia Mining 18.4% (Fe) Jianlong Group PE Investment 26.7% Shanjiao Wulin Platforms(1) 20.0% (Coking coal) Note: 1. Fosun’s PE investment platforms include Fosun Capital, Fosun Venture Capital, Focus Media Zunyi Century Principal Capital and Fosun-Carlyle. Effective stake of each platform held by (NASDAQ:FMCN) 55.0% (Mo) 25.8% Fosun Group is 100%,100%, 99% and 50%, respectively. Zhaojin Mining （01818.HK) 4 8.2% (Gold) A Growth Story

1992 2009

Founded by four college graduates Largest non-state owned conglomerate in China Initial investment of US$4,000 Book value of US$3.59 bil (as of Dec 31, 2009)

Annual Percentage Annual Percentage Annual Percentage Relative Relative Change in Per-Share Change in Change in Results Results BV of Fosun (%) Hang Seng Index (%) S&P 500 (%) Year (1) (2) (1) - (2) (3) (1) - (3)

2005 ……… 93.09 4.54 88.55 3.00 90.09 2006 ……… 40.97 34.20 6.77 13.62 27.35 2007 ……… 286.80 39.31 247.50 3.53 283.28 2008 ……… 0.43 -48.27 48.70 -38.49 38.92 2009 ……… 23.22 52.02 -28.80 23.45 -0.23

5 year CARG 67.10 8.98 58.12 -1.65 68.75

5 2009 Highlights

¾ The group reported a record high net profit of RMB 4.65 bil with a 250% Y-o-Y increase, marking a quick recovery from financial crisis

— Non-cyclical businesses delivered stable and rapid growth, benefiting from China's growing domestic consumption market

— Cyclical businesses delivered remarkable performance with aggressive cost- cutting, and commanded leading status in major economic efficiency indices among industrial peers

— Substantial value of shareholders was unlocked through Sinopharm’s successful listing

¾ Identified and captured value investment opportunities with 15 strategic investments being completed, at a total initial cost of RMB 1.58 bil

¾ RMB 15.4bil worth of funds raised and secured by fully leveraging China’s unique easing financing policy

¾ Substantial progress being achieved in wealth management

¾ Great efforts being initiated in establishing global investment platform 6 2009 Financial Review Financial Review – Key Financial Measures

Revenue declined due to the plunging steel and iron ore prices; while record-high net profit was delivered, as a result of improved operational performance, as well as investment appreciation.

(in RMB Mil) 2009 2008 YOY (%)

Revenue 34,856 40,250 -13.4%

Gross profit 5,694 8,029 -29.1%

Net Profit Attributable to Shareholders 4,647 1,328 249.9%

EBITDA 11,205 6,887 62.7%

EPS (RMB) 0.72 0.21 242.9%

BV per share (RMB) 3.81 3.09 23.3%

Dividend per share (HKD) 0.164 0.08 100.0%

Share price (monthly average of Feb, 2010, HKD) 5.52

8 Financial Review – Net Profit by Segment

Swift recovery from the impact of financial crisis in all segments. Substantial profit increase was achieved in all segments except for mining.

(in RMB Mil) 2009 2008 YOY (%)

Pharmaceuticals 1,185.6 261.4 353.6%

Property Development 327.3 57.6 468.2%

Steel 1,068.1 118.0 805.2%

Mining 235.6 1,285.1 -81.7% Retail, Services and Strategic 2,308.3 -14.6 Turn around Investments HQ Expenses -347.4 -208.3 N.A

Eliminations -130.8 -170.8 N.A

9 Financial Review – Balance Sheet Summary

Financial structure remained sound and stable, with sufficient cash and unused bank credit facilities; Debt structure continued to be optimized with mid-to-long term debt ratio being increased by year

in RMB Mil 2009/12/31 2008/12/31 Change (%)

Cash & Bank Balance 15,948 11,691 36.4% Net Cash at Holding Level 1,384 1,972 -29.8% Unused Bank Credit Facilities 22,410 19,055 17.6% Operating Cash Flow 5,456 1,295 321.3%

Total Asset 88,154 69,772 26.4%

Book Value 24,484 19,870 23.2%

Total Debt/Total Capitalization(1) 44.2% 45.0% -0.8ppt

Net Debt/Net Capitalization(2) 26.1% 30.0% -3.8ppt

Mid/Long-term Debt/Total Debt 41.7% 38.0% 3.7ppt

Notes: 1. Total Debt = current & non-current interest-bearing borrowings + interest-free loans from related parties Total Capitalization = total equity + total debt 10 2. Net Debt = total debt – cash & bank balance Net Capitalization = total equity + net debt 2009 Business Review 2009: Macroeconomic Overview

Global： China： ― World economy remained weak at ― 4 trillion economic stimulus package the cyclical bottom proved to be effective, and China’s economy resumed strong growth Global GDP: down by 2.2% • GDP: increased by 8.7% ― Relaxed monetary / credit / financing ― International capital markets are policies were adopted slow in recovery of its capital raising functions • 9.59 trillion of new RMB loans was placed, registering a 95.3% y-o-y increase

― US and European unemployment • 834.6 billion RMB was raised through equity market rates remain high ― Domestic market growth accelerated with per capita income continued to ― Consumer demand in developed grow countries remain weak • Total domestic consumption (excluding the price factor) increased by 16.9% y-o-y ― Concerns growing over sovereign Urban disposable income per capita grew wealth debt uncertainty • 9.8% y-o-y

12 Source: World Bank, National Bureau of Statistics of China, China Venture 2009 Business Review Management Improvement of Current Portfolio Companies Operational Improvement — Fosun Pharma

Pharmaceutical industrial trends in 2009: ― Market expansion boosted by Chinese government’s increased investment in health-care ― Chinese pharmaceutical industry’s integration accelerated ― Chinese pharmaceutical companies speeded up the pace of international expansion

Highlights of Fosun Pharma:

¾ Record-high performance driven by internal growth, external expansion and industry integration — Integration of pharmaceutical manufacturing businesses created significant synergies — Sinopharm seized industrial integration opportunities, and maintained rapid growth — Construction of industrial chain by strengthening investments in good companies — Continuously invest in R&D for product innovation

¾ Unlock shareholder value by attracting sophisticated capitals

14 Operational Improvement — Fosun Pharma

R&D Expense As % of Revenue

R&D (2009) 89 patents filed for approval 26 patent applications granted

New R&D platforms (2009) ―Small molecule chemical drugs ―Monoclonal antibody ―High-end generic drugs

15 Operational Improvement—Sinopharm

收入6 year6年CAGR: CAGR: 34.1%34.1%

Network Coverage（2009）： ―Added 4 provinces to a total network 6净利润 year5 年CAGR:CAGR: 53.3%53.3% coverage of 23 provinces

Total Clients（2009）： ―Direct clients include ~42.3% of all hospitals in China ―Additional 31,992 clients, with increasing leadership gap 16 Operational Improvement—Forte

¾ Property development industrial trends in 2009

― Market recovered rapidly, backed by strong rigid demand ― Seller’s market, mid to long-term upward trend unchanged

¾ Highlights of Forte

― Increased project reserves ― Robust growth of sales target for 2010 ― Continued to finance from multiple sources

17 Operational Improvement—Forte

Forte Industry Average(1) Y-o-Y Change of Attributable Contract Sales GFA in 2009: …………… 150.3% 60.9% Y-o-Y Change of Attributable Contract Sales in 2009: …………… 169.1% 69.8% Y-o-Y Change of Attributable Booked GFA in 2009: …………… 59.9% - Y-o-Y Change of Attributable Booked Sales in 2009: …………… 73.0% - Newly added land banks in 2009 …………… 1.43 mil sq.m.

Note: 1. Average level of Vanke, Poly, Gemdale, China Shipping Development and R&F (calculated by data published in the annual reports of respective companies) 8,517 5,680 7,345 892 577

3,282 361

356 3,165 6,849

2008 2009 2008 2009 200 2009 2008 2009 2008 2009 Attr. Contract Attr. Contract Attr.8 Booked Attr. Booked Attr. 18 Sales GFA Sales GFA Sales Project Reserve ‘000 sq.m. Rmb Mil ‘000 sq.m. Rmb Mil ‘000 sq.m. Operational Improvement—NSU

¾ Steel industrial trends in 2009 ― Entire industry hovers at the bottom of the cycle ― Sharp decline in steel prices led to an overall profit drop in the industry ― Driven by investment and consumption recovery in 4Q, steel production reached 565 million tons, higher than market expectation at the beginning of 2009 (1)

¾ Highlights of NSU ― Production reached a record high of 6.01 million tons, sales/ production ratio reached 100%, further solidified its market position in the medium-and-heavy plate sector ― Continued to lead in the operational efficiency with composite economic efficiency index ranked No.1 in the industry (1) ― Breakthrough in product innovation with increased percentage of high gross margin products ― Improved the overall management. Awarded National Quality Award - the highest honor in the field

Note: 1.Source: CISA 19 Operational Improvement—NSU

Key performance indicators： Rankings of economic efficiency indices (1) 2009 2008 Y-o-Y Jan-Nov, 09 Composite economic #1 Pig iron output (Mil tons) 6.03 5.14 17% performance index Production per capita #1 Crude steel output (Mil tons) 6.50 5.74 13% Return on capital #1 Steel product output (Mil tons) 6.01 5.19 16% EBT per capita #2 Sales/production(%) 100 100 — Earning per capita #3 Utilization rate of capacity (%) 98.5 85.1 — Return on total asset #4

Return on equity #5

Note: 1. Data source from CISA Prices of steel products and raw materials

RMB/ton 2009 2008 Change

ASP of steel products ………………………… 3,571 5,248 -1677 Average purchasing cost of iron ore ………………………… 682 1,077 -395 Average purchasing cost of coking coal ………………………… 1,052 1,399 -347 20 Operational Improvement—Hainan Mining

¾ Iron ore industrial trends in 2009:

— The whole industry hovers at the bottom, international long-term contract price of concentrated fines fell by 32.9% in comparison with 2008

— Comparing with foreign counterparts, domestic enterprises generally have higher production cost, thus less competitive

¾ Highlights of Hainan Mining

— Production continued to increase, reaching 3.41 million tons, with sale / production ratio achieving 98.5%

— Maintained stable customer base. Direct sales as % of total sales continued to rise, achieving a high gross margin of 63% despite the low price level

— Effectively cut cost and improved the overall operational efficiency. The average production cost of ore is 155 yuan/ ton, with the cash cost at 122 yuan/ ton

— Reserves continued to increase, which will ensure a sustainable future growth 21 Operational Improvement—Hainan Mining

Key operation indicators

2009 2008 Change

Total output（mil tons） ………………… 3.41 2.75 24%

Weighted ASP of iron ore products（RMB/ton） ………………… 423 811 -48%

Cash cost（RMB/ton） ………………… 122 179 -32%

Average production cost (RMB/ton） ………………… 155 213 -27%

Gross margin（%） ………………… 63% 74% -11ppt

Sales from top 10 clients (mil tons) ………………… 3.09 2.52 23%

Sales from top 10 clients as % of total sale ………………… 93% 89% 4%

Iron ore reserves（mil tons） ………………… 265 221 20%

22 2009 Business Review Investments and Returns New Investment Activities in 2009

Fosun Group Actively seeking growth opportunities through investing

Industrial investments: 14 projects of 475.1 mil RMB

Pharmaceuticals Strategic investments: 15 projects of 1.58 bil RMB Land banks and others: 3.64 bil RMB Property Development Investment proportions by project characteristic for strategic investments:

Steel

Proportion of Investment Strategies total investment Mining Assets with good liquidity (post-IPOs） 66%

Retail, Services Assets benefiting from growing domestic consumption market 61% and Strategic (eg: Yashili, Jiangxi Guohong） Investments 24 24 Overview of Industrial Investment Projects(1)

Listed Industrial Investment Projects In RMB Million

Initial Investment Investee Initial Investment Amount IRR(2) Time

1994 ………………………….. Fosun Pharma 18 51.20% 1998 ………………………….. Forte 19 47.30% 2001 ………………………….. Yuyuan 354 43.40%

Unlisted Industrial Investment Projects In RMB Million

Initial Net Profit Net Asset Accumulated Initial Investment Investee attributable to attributable to Fosun Dividends received Investment Time Fosun in 2009 as of Dec. 31, 2009 as of Dec. 31, 2009

2001 ………… Jianlong 351 420 1563 400 2003 ………… NSU 1650 671 2955 1572 2007 ………… Huaxia Mining 17 10 504 55 2007 ………… Hainan Mining 900 273 1174 703 2007 ………… Shanjiaowulin 301 -27 276 - 2007 ………… Yong’an Insurance 328 8 107 - 2008 ………… Zunyi Century 190 -98 106 - Total 3,737 1258 6684 2731

Notes: 1. All industrial investment projects with investor of Fosun Group/Fosun International and a duration of over 24 months, as of February 28, 2010. 25 2. Listed companies’ assets are calculated with market value, as of December 31, 2009 Overview of Strategic Investment / Pre-IPO Projects

Substantial value to be unlocked from existing strategic investments and pre-IPO investments(1)

Summary: 36 projects with ~5.3 bil RMB of initial investment amount

Holding level: • 11 projects with ~ 3 bil RMB of initial investment amount • 76% post-IPOs, 24% pre-IPOs (by cost)

Subsidiary level: Fosun Pharma: • 23 projects of ~1.6 bil RMB of initial investment amount • 23% post-IPOs, 77% pre-IPOs (by cost) Forte: • 2 projects of ~0.7 bil RMB of initial investment amount • 97% post-IPOs, 3% pre-IPOs (by cost)

Note: 1. Strategic investment projects and pre-IPO investments by Fosun and its subsidiaries as of Feb. 28, 2010 26 IRRs of Listed Strategic Investment Projects

Listed strategic investment projects In RMB Million Initial Company Stock CodeTotal Investment IRR(1) Investment Time

2000 Lingrui 600285.SH 30.7 19% 2003 Zhejiang Hisoar 002099.SZ 27.0 73% 2004 Zhaojin Mining 01818.HK 160.7 55% ZJ Quartz Crystal 2006 002273.SZ 22.0 334% Optoelectronic Tech 2007 Befar (2) 601678.SH 150.0 140%

Strategic investment in listed companies In RMB Million

Initial Total Corresponding Market Company Stock Code IRR(1) Investment Time Investment Value (2010/2/28） 2007 Shanghai Zendai 00755.HK 703.0 778.2 NA 2008 Focus MediaFMCN.Nasdaq 2,085.2 3,969.7 148% 2008 Tongjitang TCM. NYSE 190.2 201.1 24% 2009 Chindex CHDX.Nasdaq 150.0 116.9 NA

Notes: 1.IRRs of listed companies are calculated with market value as of Dec 31, 2009 2.IRR of Befar is calculated with market value as of Feb 28, 2010 27 2009 Business Review Financing from multiple sources 2009 Financing Activities

¾ Optimized debt structure by completing a number of long-term debts, with reduced financing cost

9 NSU ...……………...……...... 6.13% 7 years RMB2.5 bil Enterprise Bond The first company under macroeconomic management that issue enterprise bond

9 Yuyuan ……………………….. 5.90% 5 years RMB 500 mil Corporate Bond The first company that got the approval of issuing enterprise bond in 2009

9 Forte ………………………... 7.30% 5 years RMB 1.9 bil Corporate Bond The first Hong Kong-listed company that issued corporate bond in Mainland China

9 Zhaojin Mining ………………………... 5.00% 7 years RMB 1.5 bil Corporate Bond

¾ Captured the capital market recovery opportunity, started the re-financing of listed companies and the initial listing of qualified companies

9 Fosun Pharma： Proposed to issue 20-46 mil A shares …...……...... Approved

9 NISCO ： Proposed to issue 2.17 bil A shares as consideration for injected asset of NSU …... Announced

9 Forte： Proposed to issue 285 mil A shares ...... Announced

9 IPO： ― Listed：Sinopharm （Sep 2009, HK） / Befar （Feb 2010, SH）

― Approved：ShaanGu Power（Jan 2010）‖ ASD （Feb 2010）‖Hansen（Feb 2010） 29 2009 Financing Activities (Continued)

¾ Progress in the asset management business

9 Forte: Established a real estate fund, with RMB 550 million as starting capital 9 Fosun-Carlyle Shanghai Equity Investment Enterprise: First foreign-funded partnership equity investment enterprise in China（2/2010） • First co-GP arrangements with institutional partners in both companies’ histories

¾ Strictly implemented dividend policy for portfolio companies

9 Dividend of 2009 reached RMB 792 mil ¾ A realisation of RMB 1.903 bil through strategic divestments

30 Vision and Outlooks Our Vision

¾ To become the world's leading conglomerate

― With extensive and profound industrial base ― Captures global investment opportunities that benefit from China's economic growth ― Establishes a global investment platform that integrates both domestic and international resources

32 Our Growth Plan

¾ Current strengths ― Well recognized local investment brand ― Team of experienced entrepreneurs ― A solid industrial base ― Rich financial and government resources

¾ Development path Continue to develop three core competencies • Actively seeking low-cost and sustainable sources of funding to increase the size of assets under management Continue to capture major investment opportunities at home and abroad that benefit from China’s economic growth

Fully integrate with international resources ¾ International vision and mentality ¾ International teams 9 Localized teams in various regions 9 Professional local partners ¾ Global fund-raising capacity ¾ Global investment capacity 33 Priorities for 2010

¾ Optimize management — Improve the operational efficiencies in all segments ¾ Pharmaceuticals: To achieve stable and rapid growth by the internal drive, external expansion and industrial integration ¾ Property development: Dual focus on both development and investment to seek risk-controlled high growth ¾ Steel: Continue to cut cost and improve operational efficiency, and focus on product innovation to increase high-margin products, with the overall goal of reaching production capacity of 8 million tons ¾ Mining: Cut cost and actively develop new markets to strengthen competitiveness and maximize profitability — Promote industrial chain integration in various segments

¾ Invest in China’s growth momentum — Adhere to value investment philosophy and invest in strategic assets at reasonable costs — Invest in industries that benefit from China’s domestic demand — Invest in overseas assets that benefit from China's economic development — Pay close attention to investment opportunities of which the targeted companies have overseas integration capabilities

¾ Financing from multiple sources ― Encourage qualified companies to start the initial listing process ― Expedite the listing process of certain pre-IPO projects ― Continue to attract quality capital 34 ¾ Build international investment platform 2010 operational targets

NSU: Steel Production Hainan Mining: Iron Ore Production

100,000 tons 100,000 tons 63 36.5 60 33.6 52.2 28.3

2008 2009 2010F 2008 2009 2010F

Jin’an Mining: Iron Ore Production Forte: Pre-Sale & Booked GFA

100,000 tons 9 8.3 100,000 sq.m 6.3

35 2008 2009 2010F Welcome to 2010 Shanghai World Expo

Welcome to Fosun Welcome to The Chinese Private Enterprise Pavilion

Welcome to Fosun Presentation Appendix Fosun’s Previous Achievement

38 2004-2009 CAGR - Key Financial Indicators

Revenue Total Asset 2004-2009 CAGR: 14.1% 2004-2009 CAGR: 22.4%

Net Profit Net Asset 2004-2009 CAGR: 29.4% 2004-2009 CAGR: 75.7%

39 2004-2009 CAGR – EPS & Book Value

Book value per share 2004-2009 CAGR: 67.1%

EPS 2004-2009 CAGR: 23.1%

40 2004-2009 ROE / ROA

ROE

ROA

41 Market Value of Fosun Portfolio Companies in 2009

Dec 31, 2009 Company Equity Ratio Attributable Market Share Price Value Fosun 49.03% RMB 19.57 RMB 11,877 Pharma Forte 61.00% HKD 2.54 HKD 3,919

NSU 37.61% RMB 6.09 RMB 3,859

Yuyuan 17.26% RMB 27.33 RMB 3,766

Focus Media 25.80% USD 15.85 USD 597 Zhaojin 3.60% HKD 15.48 HKD 855 Mining Total (RMB Mil) 27,779 Total (HKD Mil) 31,567

42 Fosun’s Investment Philosophy and Value Creation

43 Fosun’s Investment Principles and Strategies

A business model carrying strengths from Berkshire and GE while customized to win against the backdrop of China’s growth Fosun Disciplined long term value investor Yes Berkshire Secured, sustained and low cost funding In progress

Add value to investees by active Yes GE management improvement One operational model applies all No

Our strategies: Step 1: identify the right industry to enter Step 2: identify and invest in good companies with value Step 3: improve management efficiency by working with the original team Results: boost returns by transforming a good investment target into an

excellent portfolio company 44 Criteria for Industries

To invest in China’s growth momentum

China’s growth momentum Fosun Group All profits rooted from China

Over 1.3 bil population Non-cyclical business with vast market expansion Pharmaceuticals opportunities

An aging population Quick industry recovery; benefiting from China’s vast Property Development pendant demand and growing domestic purchasing Increase of power in a mid-to-long term perspective disposable personal income Retail, Services and Benefiting from China’s growing domestic consumption market Strategic Investments Sustained urbanization and industrialization Industry recovering from its cyclical bottom; benefiting from Steel China’s industrialization and urbanization process and its role as the global manufacturing base, in a mid-to-long term Manufacturing base for global tangible Scarcity of resources in a long term determines its great products Mining investment potential 45 Criteria for Companies

Management Team Corporate Governance Concrete Criteria Entrepreneurship Operating strictly according Industry-leading position to corporate guidelines Stable and balanced Strong profit history and Financial transparency opportunities Flexibility of transformation Potential high returns Reasonable valuation Over 24 months continuous operating history

Three Key measurements: 1.Forecasted Cash Flow 2.Operating Cost (top 50% among industrial peers) 3.Investment Cost (top 50% among our peers)

46 Fosun’s Value-Added – Investment of Sinopharm

Sinopharm

Investor: Fosun Pharma Initial investment: 500 mil RMB Time of investment: 2003 Stake held: 47% (before listing) / 34% (after listing) IPO price: HKD16 per share Market value (Dec. 31, 09): 8.04 bil USD (54.8 bil RMB) Attributable market value held by Fosun Pharma(Dec. 31, 09): 2.73 bil USD (18.6 bil RMB) IRR (Dec. 31, 09) : 104.9%

Before Fosun 2009 Sales ~6 bil RMB 47 bil RMB with 6-year CAGR of 34.1% Net Profit ~15 mil RMB 846 mil RMB with 6-year CAGR of 53.3% Market Position 2nd in the industry by revenue 1st in the industry with market share increased year by year

47 Fosun’s Value-Added – Investment of Sinopharm

Fosun’s involvement in management improvement of Sinopharm •Setting-up and optimizing of overall strategy (by the board of directors) 9Company strategy: organic growth/M&A/business integration 9Key indicators for performance assessment: cash flow & growth rate 9Management tools: integrated procurement platform, ERP system, etc • Choosing excellent managerial talents for key management teams • Establishing effective incentive packages for key management teams

48 Fosun’s Value-Added – Iron and Steel

Changes before and after Fosun’s participation

NSU（Invested in 2003, partially listed）

Before Fosun Present

Crude Steel Capacity ~2 mil tons 6.5 mil tons (reach 8.0 mil tons by 2010) Production base for premium plates ( high strength ship ~ 30％ commodity ship plates and others) Product Mix plates New production line for alloyed bars and wire rods with capacity over 600,000 tons Mid-sized state-owned 3 economic efficiency indices ranked No. 1 among the Economic Benefit steel company with a whole industry, including composite economic long history performance index

Hainan Mining (Invested in 2007, unlisted）

Before Fosun Present

Relied on two major clients - More than 10 major clients, market–oriented Clients Base weak negotiation power pricing mechanism Sales Model Relied on brokers/agents Direct sale model 13.16% in 2006 before Profitability (ROE) 23.28% reorganization 49 Fosun’s Core Competency and Intrinsic Value

50 Three Value Chains

Optimized Financing Added value by the holding group from Multiple Sources To invest： Actively participate in industrial M&A and share the benefits of China’s economy growth

Management Team with Capture To manage： Enhance competitiveness and Entrepreneurial Investment profitability of invested companies to Spirit Opportunities improve return on investment Benefiting Continuous from China’s Management Economic Improvement To ensure safe and low-cost financing Growth To finance： by exploring all potential channels and platforms

To recruit talents： United talents with entrepreneurial spirits

Our culture: to unite growth forces Our mission: to consolidate all group resources to serve the value chains 51 The Core Management Team

Young and Energetic Founders

Mr. Guo Guangchang Mr. Liang Xinjun Founder 43 Founder 42 Chairman Vice Chairman & CEO Executive Director Executive Director

Mr. Fan Wei Mr. Wang Qunbin Founder 41 Founder 41 Executive Director President Chairman of Forte Executive Director

Experienced and Stable Core Management Team

Mr. Ding Guoqi Mr. Wu Ping Executive Director 41 Executive Director 46 Senior VP / CFO Senior VP Over 14 years in Fosun Chairman of Yuyuan Over 13 years in Fosun

Mr. Qin Xuetang 47 Dr. Zhou Linlin 49 Executive Director Vice President Senior VP Over 6 years in Fosun Over 14 years in Fosun Fosun’s Intrinsic Value

Fosun’s intrinsic value

Key portfolio Strategic Funds available Group’s value companies +++investment for investment creation

Fosun Pharma Financing Pre-IPO capability （listed） Cash Forte Investment Pre-IPO capability （unlisted） NSU Equivalent Management optimization Jianlong Unused bank Post-IPO facility Brand Hainan Mining Government Yuyuan resources